Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance

Thiru Prasanna, Fan Wu, Desmond Yip, Sudha Rao

Research output: Contribution to journalEditorial


Immunotherapy has revolutionized anticancer therapy over the last decade, with impressive responses seen in many patients and six immune checkpoint inhibitors (ICIs) now approved by the US FDA for the treatment of solid organ malignancies [1]. The best responses and survival benefits are seen in melanoma patients, with approximately 60% of patients treated with combination immunotherapy (anti-CTLA4 and anti-PD-1 inhibition) still alive at 3 years [2]. However, many patients with advanced solid organ malignancies have suboptimal responses or acquire resistance relatively quickly. There is therefore a real clinical imperative to find ways to optimize immunotherapy and overcome ICI resistance with intense research interest in this area.
Original languageEnglish
Pages (from-to)1263-1266
Number of pages4
Issue number15
Early online date29 Aug 2019
Publication statusPublished - Oct 2019


Cite this